GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai Kehua Bio-engineering Co Ltd (SZSE:002022) » Definitions » EBIT

Shanghai Kehua Bio-engineering Co (SZSE:002022) EBIT : ¥-281 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Shanghai Kehua Bio-engineering Co EBIT?

Shanghai Kehua Bio-engineering Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥-13 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-281 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Kehua Bio-engineering Co's annualized ROC % for the quarter that ended in Mar. 2024 was -1.98%. Shanghai Kehua Bio-engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Kehua Bio-engineering Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -12.12%.


Shanghai Kehua Bio-engineering Co EBIT Historical Data

The historical data trend for Shanghai Kehua Bio-engineering Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kehua Bio-engineering Co EBIT Chart

Shanghai Kehua Bio-engineering Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 355.72 1,390.99 1,677.55 2,105.24 -141.87

Shanghai Kehua Bio-engineering Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.59 -1.00 -17.95 -249.50 -12.63

Competitive Comparison of Shanghai Kehua Bio-engineering Co's EBIT

For the Medical Devices subindustry, Shanghai Kehua Bio-engineering Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Kehua Bio-engineering Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai Kehua Bio-engineering Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Kehua Bio-engineering Co's EV-to-EBIT falls into.



Shanghai Kehua Bio-engineering Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-281 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kehua Bio-engineering Co  (SZSE:002022) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Kehua Bio-engineering Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-94.268 * ( 1 - 11.34% )/( (4151.657 + 4275.714)/ 2 )
=-83.5780088/4213.6855
=-1.98 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6807.74 - 708.419 - ( 1947.664 - max(0, 902.918 - 4316.244+1947.664))
=4151.657

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6620.133 - 643.767 - ( 1700.652 - max(0, 817.399 - 4142+1700.652))
=4275.714

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Kehua Bio-engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-50.5/( ( (939.887 + max(1510.031, 0)) + (927.411 + max(1666.312, 0)) )/ 2 )
=-50.5/( ( 2449.918 + 2593.723 )/ 2 )
=-50.5/2521.8205
=-2.00 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1102.241 + 975.434 + 229.772) - (708.419 + 0 + 88.997)
=1510.031

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1113.732 + 1013.049 + 250.345) - (643.767 + 0 + 67.047)
=1666.312

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Kehua Bio-engineering Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-281.082/2318.969
=-12.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Kehua Bio-engineering Co EBIT Related Terms

Thank you for viewing the detailed overview of Shanghai Kehua Bio-engineering Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kehua Bio-engineering Co (SZSE:002022) Business Description

Traded in Other Exchanges
N/A
Address
No. 1189 Qinzhou North Road, Xuhui District, Shanghai, CHN, 200233
Shanghai Kehua Bio-engineering Co Ltd is a developer, manufacturer, and marketer of in-vitro diagnostics business in China. Its products are mainly offered in two primary business segments: Diagnostic Reagents and Diagnostic Laboratory Instruments. Its products include diagnostic reagents, such as enzyme-immunoassay kits, clinical chemistry reagents, PCR kits, and rapid test kits and lab-instruments comprising chemistry analyzers, microplate washers/readers, electrolyte analyzers, and nucleic acid extractors.
Executives
Li Ming Executives
He Jian Wen Executives
Ji Yu Ming Supervisors
Li Ji Executives
Sha Li Wu Director
Wang Man Directors, executives
Tang Wei Guo Director

Shanghai Kehua Bio-engineering Co (SZSE:002022) Headlines

No Headlines